Skip to main content

Novel BMSC delivery of combination gene therapy for treatment-resistant metastatic prostate cancer: Non-invasive molecular and functional imaging in immune intact mouse models.

Funding or Partner Organisation: Sydney Vital (Sydney Vital Flagship 1 Seed Funding)

Start year: 2015

Summary: Prostate cancer (PCa) seeking adult stem cells (BMSC) will be engineered to produce a secreted factor that kills PCa by the stimulation of the immune system and a suicide factor. The suicide factor may be "switched on" with a prodrug to further destroy nearby tumour cells. Together, this will produce a BMSC therapeutic factory for infusion into the bloodstream to "seek and destroy" PCa anywhere in the body. This study will provide a novel treatment for treatment resistant metastatic PCa which is currently incurable.

Publications:

Gerace, D, Martiniello-Wilks, R, Habib, R & Simpson, AM 2019, 'Luciferase-based reporting of suicide gene activity in murine mesenchymal stem cells', PLOS ONE, vol. 14, no. 7, pp. e0220013-e0220013.
View/Download from: Publisher's site

Habib, R, Brennan, S, Tan, M, Larsen, SR & Martiniello-Wilks, R 2015, 'UNDERSTANDING AND HARNESSING MESENCHYMAL STEM CELL HOMING TO METASTATIC PROSTATE CANCER', WILEY-BLACKWELL, pp. 200-201.

Suurbach, JH, Habib, R, Brennan, S, Larsen, SR, Simpson, A & Martiniello-Wilks, R 2015, 'CELLULAR AND GENETIC MEDICINES ADVANCING THE TREATMENT OF METASTATIC PROSTATE CANCER', WILEY-BLACKWELL, pp. 198-199.

Keywords: Prostate Cancer, gene therapy, adult stem cells

FOR Codes: Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Men's Health